BioLineRx financials at a glance

+ Portfolio

The revenue of BioLineRx is reported as 0.0018 billion New Shekels in the fiscal year 2023. The earnings were 0 New Shekels per share in 2023, which was 6.67 higher than 2014. And about -0.0002 billion New Shekels are reported as free cash flow in the financials of BioLineRx 2023. No dividends were paid to the shareholders of the BioLineRx stock TASE:BLRX in the financial year 2023.

Forecast

Financials

Year	Year	TTM	2015	2014	2013	2012	2011
Rev.	Revenue	N/A	₪0.00M	₪0.00M	₪0.00M	₪0.00M	₪0.00M
GM %	Gross Margin %	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
OM	Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	Earnings Per Share	₪-0.06	₪-0.28	₪-0.30	₪-0.80	₪-1.20	₪-1.10
Div.	Dividends	N/A	₪0.00	₪0.00	₪0.00	₪0.00	₪0.00
PR %	Payout Ratio %	0	0	0	0	0	0
Sha.	Shares	N/AM	54.82M	39.12M	24.15M	22.95M	17.61M
OCF	Operating Cash Flow	N/A	₪0.00M	₪0.00M	₪-20.37M	₪-20.13M	₪0.00M
FCF	Free Cash Flow	N/A	₪-16.85M	₪-14.41M	₪-20.46M	₪-20.73M	₪0.00M
FCFS	Free Cash Flow Per Share	₪-0.04	₪-0.33	₪-0.49	₪-0.87	₪-4.47	₪-3.55

BioLineRx financials at a glance

Financials

Discover